文献速递认知障碍与痴呆帕金森病与运动障碍

帕金森病中Tau蛋白、β-淀粉样蛋白与认知的关联

Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项横断面研究纳入29例帕金森病患者(15例认知正常,14例轻度认知障碍)和49名健康对照,进行tau PET、Aβ PET和认知评估。结果显示,帕金森病认知正常与轻度认知障碍患者之间脑内tau沉积无显著差异,且与Aβ阴性健康老年人无差异;tau沉积与Aβ状态和年龄相关。无痴呆帕金森病患者的认知缺陷似乎并不反映可测量的阿尔茨海默病病理。

要点

  • 帕金森病认知正常与轻度认知障碍患者之间tau PET摄取无显著差异。
  • 帕金森病患者脑内tau沉积与Aβ阳性状态和年龄相关。
  • 无痴呆帕金森病患者的认知缺陷似乎不反映可测量的阿尔茨海默病病理。

核心结论

  • 帕金森病认知正常、轻度认知障碍和健康老年人的皮层Aβ与tau模式无差异。
  • 年龄、Aβ和tau不能区分帕金森病认知正常与轻度认知障碍患者。
  • 在帕金森病患者和健康老年人中,tau沉积与Aβ状态和年龄相关。
  • 无痴呆帕金森病患者的认知缺陷似乎不反映可测量的阿尔茨海默病病理。

研究设计与样本

  • 1例轻度认知障碍患者因未接受MRI扫描被排除,最终纳入29例帕金森病患者进行分析。
  • 参与者接受氟18标记AV-1451的tau PET扫描、碳11标记匹兹堡化合物B的Aβ PET扫描、MRI、认知测试和神经科评估。
  • 影像学指标与49名健康对照参与者进行比较。

主要发现

  • 78名参与者中47名(60%)为女性,平均(SD)年龄为71.1(6.6)岁。
  • 6例帕金森病患者(21%)为Aβ阳性,其中1例为轻度认知障碍;23例(79%)为Aβ阴性。
  • 49名健康对照中,25名为Aβ阴性,24名为Aβ阳性。
  • 全脑tau PET摄取在帕金森病认知正常与轻度认知障碍患者之间、以及所有帕金森病患者与Aβ阴性对照之间均无显著差异。
  • 在反映阿尔茨海默病Braak分期1/2、3/4或5/6的脑区,帕金森病轻度认知障碍与认知正常患者之间tau PET结合无差异,且与Aβ阴性健康老年人无差异。

临床怎么用

  • 对于无痴呆的帕金森病患者,认知障碍的评估不应默认归因于阿尔茨海默病病理。
  • tau PET和Aβ PET可用于研究目的,但在帕金森病认知障碍的常规临床区分中价值有限。
  • 应考虑年龄和Aβ状态对tau沉积的影响,尤其在解释帕金森病患者tau PET结果时。

局限性

  • 横断面设计无法推断因果或纵向变化。
  • 样本量较小(29例帕金森病患者),可能限制统计效能和普遍性。
  • Aβ阳性帕金森病患者仅6例,亚组分析结果需谨慎解读。
  • 研究排除未接受MRI扫描的1例患者,可能引入选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Multiple disease processes are associated with cognitive impairment in Parkinson disease (PD), including Lewy bodies, cerebrovascular disease, and Alzheimer disease. It remains unknown whether tau pathology relates to cognition in patients with PD without dementia. OBJECTIVE: To compare tau aggregation in patients with PD who are cognitively normal (PD-CN), patients with PD with mild cognitive impairment (PD-MCI), and healthy control participants, and evaluate the relationships between β-amyloid (Aβ), tau, and cognition in patients with PD who did not have dementia. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study recruited 30 patients with Parkinson disease (15 with PD-CN and 15 with PD-MCI) from a tertiary care medical center and research institutions from July 2015 through October 2016. One patient with PD-MCI did not receive a magnetic resonance imaging scan and thus was excluded from all analyses; 29 patients with PD were included in the present study. Participants underwent tau positron emission tomographic (PET) scanning with fluorine 18-labeled AV-1451, Aβ PET scanning with carbon 11-labeled Pittsburgh compound B, magnetic resonance imaging, cognitive testing, and neurologic evaluation. Imaging measures were compared with 49 healthy control participants. MAIN OUTCOMES AND MEASURES: Outcomes were tau PET measurements of groups of patients with PD-CN and PD-MCI. We hypothesized that tau aggregation across groups would be related to age and Aβ status. RESULTS: Of the 78 participants, 47 (60%) were female, and the mean (SD) age was 71.1 (6.6) years. Six patients with PD (21%) were Aβ-positive, of whom 1 was mildly cognitively impaired; 23 were Aβ-negative (79%). (Of the 49 healthy controls, 25 were Aβ-negative and 24 Aβ-positive.) Voxelwise contrasts of whole-brain tau PET uptake between patients with PD-CN and patients with PD-MCI, and additionally between all patients with PD and Aβ-negative controls, did not reveal significant differences. Tau PET binding did not differ between patients with PD-MCI and PD-CN in brain regions reflecting Alzheimer disease Braak stages 1/2, 3/4, or 5/6, and did not differ from Aβ-negative healthy older adults. Mean (SD) tau PET binding was significantly elevated in Aβ-positive patients with PD relative to Aβ-negative patients with PD within brain regions reflecting Alzheimer disease Braak stage 3/4 (1.22 [0.07] vs 1.14 [0.07]; P = .03) and Braak stage 5/6 (1.20 [0.07] vs 1.11 [0.08]; P = .02). CONCLUSIONS AND RELEVANCE: These findings suggest that patterns of cortical Aβ and tau do not differ in people with PD-CN, people with PD-MCI, and healthy older adults. Age, Aβ, and tau do not differentiate patients with PD-CN and PD-MCI. Tau deposition is related to Aβ status and age in both people with PD and healthy older adults. Cognitive deficits in people with PD without dementia do not appear to reflect measureable Alzheimer disease.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Winer JR, Maass A, Pressman P, et al. Associations Between Tau, β-Amyloid, and Cognition in Parkinson Disease. JAMA Neurol. 2018. PMID: 29228071. doi:10.1001/jamaneurol.2017.3713

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。